NCT04035278已完成1 期
A Phase 1, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Dengusiil in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Solicited local and systemic reactions
研究概览
简要总结
This is a Phase 1 study to assess safety and tolerability of a single subcutaneous dose of Dengusiil in healthy adults of 18 to 45 years of age. In this study, immune response to Dengusiil will also be assessed over a period of 6 months and vaccine viremia will also be assessed over a period of 12 days after administration of vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 18-45, men, or women.
- •Seronegative for Dengue NS1 and IgM at screening indicating no current dengue infection
- •Seronegative for dengue IgG at screening
- •Participants who are willing to comply with the requirements of the study protocol and attend scheduled visits.
- •Participants who give written informed consent approved by the Human Research Ethics Committee (HREC) governing the site.
- •Participants must have the laboratory parameters within normal range.
- •Participants with Body Mass Index (BMI) between 18 to 30 (both inclusive)
- •Satisfactory baseline medical assessment as assessed by physical examination and normal laboratory values or minor variations those are acceptable for study entry.
- •Participants should agree to not:
- •donate blood for the purpose of blood transfusion
- •donate an organ for the purpose of transplantation
- •to share needles with other people
- •allow their blood to come in contact with another person's mucous membranes for 84 days post-vaccination.
排除标准
- •Previous dengue vaccination.
- •Presence of acute infection in the preceding 14 days or presence of a temperature ≥ 38.0°C, or acute symptoms of infection greater than of "mild" severity on the scheduled date of first dosing
- •Evidence of any other significant active haematological disease, or having donated > 450 mL of blood within the past three months.
- •Evidence or history of substance abuse including alcohol or previous substance abuse within the last year.
- •Participation or planned participation in a study involving the administration of an investigational compound within the past one month or during this study period.
- •Planned administration of any vaccine not foreseen by the study protocol 4 weeks before and after dosing.
- •History of allergic disease, allergic reactions or known hypersensitivity to any component of the study vaccines.
- •Confirmed or suspected immunosuppressive or immune-deficient condition.
- •A family history of congenital or hereditary immunodeficiency.
- •Chronic administration (defined as more than 14 days) of immune-suppressants or other immune-modifying agents within six months prior to administration of study vaccine. (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day; topical or inhalable steroids are allowed.)
- •Laboratory confirmed infection with either hepatitis B virus (HBs Ag positive), hepatitis C virus (anti-HCV positive), or human immunodeficiency virus (HIV) at screening.
- •Known bleeding disorders.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the administration of study vaccines or planned administration during the study period.
- •Women who are pregnant, breast-feeding, or considering becoming pregnant.
- •Any other condition, which in the opinion of the investigator, might interfere with the study objectives, jeopardize the safety or rights of the participant or making it unlikely the participant could complete the protocol.
结局指标
主要结局
Solicited local and systemic reactions
时间窗: 21 days
Proportion of participants with clinically significant physical examination and vital signs findings
时间窗: 180 days
Occurrence, severity, and relatedness to vaccination of unsolicited adverse events
时间窗: 21 days
Occurrence, severity, and relatedness to vaccination of serious adverse events
时间窗: 180 days
Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings
时间窗: 8 days
次要结局
- The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies(180 days)
- Proportion of participants with seroconversion for DENV-1 to 4 virus neutralization antibodies (PRNT50) titer(84 days)
- GMTs of DENV-1 to 4 virus neutralization antibodies(84 days)
- Geometric mean titers (GMTs) of DENV-1 to 4 virus neutralization antibodies(56 days)
- Proportion of participants with viremia for each of DENV-1 to 4(12 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of Dengushield in Healthy AdultsPhase 1DengueNCT03883620Serum Institute of India Pvt. Ltd.40
已完成
1 期
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDSHIV/AIDSNCT02376582EuroVacc Foundation72
已完成
1 期
Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023HealthyNCT05354349Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)49
已完成
1 期
Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy SubjectsHealthy SubjectsNCT04511624Innovent Biologics (Suzhou) Co. Ltd.46
招募中
1 期
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06055361Brexogen Inc.45